𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Transdermal therapy in Parkinson's disease

✍ Scribed by Amos D Korczyn

Book ID
114408633
Publisher
The Lancet
Year
2007
Tongue
English
Weight
44 KB
Volume
6
Category
Article
ISSN
1474-4465

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Transdermal dopaminergic D2 receptor ago
Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study
✍ J. Thomas Hutton; Leo Verhagen Metman; Thomas N. Chase; Jorge L. Juncos; William πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 35 KB πŸ‘ 1 views

## Abstract N‐0923 is a non‐ergot, dopaminergic D~2~ agonist designed to be transdermally available. It has anti‐parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N‐0923 transdermally (N‐0923 TDS). In this phase II trial, we evaluated the effectiven

Pergolide therapy in parkinson's disease
Pergolide therapy in parkinson's disease
✍ P. Jeanty; M. Kerchove; A. Lowenthal; H. Bruyne πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 543 KB

A total of 26 patients were treated with pergolide mesylate, a semi-synthetic ergot derivative with the property of direct dopamine activity. Of these patients, 18 suffered from late failure of L-dopa, while the remaining 8 had never before been treated with L-dopa. The aim of the trial was to study

Initiating therapy in Parkinson's diseas
Initiating therapy in Parkinson's disease
✍ William Weiner; Eric Ahlskog; Stewart Factor; Oksana Suchowersky; Stephen Reich πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 51 KB πŸ‘ 2 views